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ABSTRACT 
 
Mutations in the human hepatitis B virus (HBV) genome contribute to its escape from 
host immune surveillance and result in persistent infections. The aim of this study was to 
characterize the molecular variations of the surface gene and protein in chronically-infected 
patients from the southern part of Iran.  
The surface genes from 12 HBV chronic carriers were amplified, sequenced and 
subsequently aligned using international and national Iranian database. 
All strains belonged to genotype D, subgenotype D1 and subtype ayw2. Of all 30 muta-
tions occurred at 22 nucleotide positions, 18 (60%) were missense (amino acid altering) and 
12 (40%) were silent (no amino acid changing). The mean mutation frequency (missense to 
silent nucleotide ratio), was 1.5, indicating application of a high positive selection pressure on 
the surface proteins. At the amino acid level, of 17 substitutions, 15 (88%) occurred in 
different immune epitopes within surface protein, of which 7 (46.6%) in B cell epitopes in 5 
residues; 7 (46.6%) in T helper epitopes in 6 positions; 1 (7%) in inside CTL epitopes in 1 
residue.  
We therefore conclude that the distribution of 93.2% of amino acid mutations inside B 
and T helper immune epitopes as well as the ratio between silent and missense nucleotide 
mutations showed a positive, focused immune selection pressure on the surface protein,  
which led to the evolution and emergence of escape mutants in these patients. 
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INTRODUCTION 
 
Hepatitis B virus (HBV) infection is among the top 
ten causes of death worldwide due to chronic liver 
disease1 and accounts for an estimated 370 million 
chronic infections.2 
The morbidity and mortality of persistent HBV 
infection are a major public health concern. More than 
one million deaths every year are due to end-stage 
HBV liver disease, such as decompensated liver 
cirrhosis and hepatocellular carcinoma (HCC).  
Hepatitis B virus surface protein (HBsAg) contains 
two loops, formed by disulfide bridges between 
cysteines 124/137 and 139/147.3 This region, 
particularly the second loop (between amino acid 139 
and 147, ‘‘a’’ determinant) is commonly described as a 
major B-cell epitope which is highly conserved and the 
anti-HBs (antibody to HBsAg) response comprises 
mainly antibodies that recognize this epitope cluster.4 
Being a structural protein, HBsAg is an immune target. 
Moreover, the humoral response to HBsAg is T-cell-
dependent. At least 4 regions within HBsAg contain 
epitopes for major histocompatibility complex (MHC)  
class II restricted CD4+ T cells.5,6 Therefore, during the 
HBV chronicity, the T-cell epitopes of HBsAg which 
are targets for T-cell recognition might be involved.7 
The distribution of the mutations within known surface 
protein immune epitopes reflects the virus-host 
interaction with a prolonged infection period.  
Mutants within immune epitopes of HBV represent a 
significant role and isolated cases of infection with HBV 
variants bearing substitutions in these regions, are 
predicted to escape from host’s immune surveillance 
(immune-escape variants). There have been increasing 
reports on the emergence of different escape mutations 
in chronic HBV carriers who did not receive hepatitis B 
immunoglobulin or vaccine8,9 distributed either within or 
outside the “a” determinant, including T cell epitopes.10 
The aim of this study was to characterize the 
molecular variations of the hepatitis B surface protein 
in chronic active patients from Southern region of Iran. 
MATERIALS AND METHODS 
 
Sera 
This cross-sectional study has been carried out on 
12 blood donors who were diagnosed to be HBsAg 
positive and subsequently, were referred from the 
Khoozestan Blood Organization. All patients were 
interviewed and examined by gastroenterologists to 
evaluate the clinical findings and the results of the 
investigative workup (liver histology, ultra sonography 
and laboratory tests such as serologic, biochemical and 
virological tests) in order to determine the clinical 
status of the patients.  They did not contain HDV, HIV 
and HCV co-infection. Informed consent was obtained 
from each patient and ethical approval for the study of 
human subjects was granted by local ethics committee. 
Samples were tested by (ELISA) with commercial 
kits for serologic detection (Diapro, Milan, Italy). Two 
ml of sera were taken from each patient and stored at -
80° C for further investigations. 
 
DNA Extraction 
HBV DNA was extracted from 200µl of each 
patient’s serum, using a QIAmp DNA Blood minikit 
(Qiagen, Hilden, Germany), according to 
manufacturer’s instructions. The eluted DNA was 
stored in -20°C. 
 
Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was carried out in 
100 µl of a mixture containing 5µl of the extracted 
DNA, using standard methodology. The complete 
surface gene was amplified using approperiate primers 
(Table 1). First round PCR was performed using 1 U of 
TaqDNA polymerase (HotStartTaqPCR, Qiagen, 
Hilden, Germany), 0.25 mM of each dNTP, 10x 
reaction buffer, 12.5 pmol of S1 and S2 primer. For the 
second round PCR, 1 µl of first round PCR product was 
added to 99 µl of the reaction mixture with the same 
composition as the first round except that S1/S2, were 
replaced by S6/S7.  
 
Table 1. Oligonucleotide primers used for PCR and sequencing. Base positions numbered from the EcoRI site. 
Primer Sequence 5'… 3' of Oligonucleotides Base Position Type 
S1 CCTGCTGGTGGCTCCAGTTC 56-75 Sense 
S2 CCACAATTC (K)TTGAC ATA CTTTCC A (K=G/T) 1003-979 Anti-sense 
S6 GCACACGGA ATT CCGAGG ACT GGGGACCCT G 113-146 Sense 
S7 GAC ACC AAG CTT GGT TAG GGT TTA AAT GTA TAC C 857-823 Anti-sense 
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DNA Sequencing 
The nucleotide sequence of the S gene was 
determined with a Genetic Analyzer sequencing ready 
reaction kit and run on an ABI- 3130 DNA Sequencer 
(Fostercity, CA, USA). The primers used for 
sequencing the S ORF are summarized in Table 1. 
Sequence analysis was performed with Chromas 
software and BioEdit Package version 7.0.9. Briefly, 
genomic sequences obtained for the HBV S gene were 
compared with all HBV genotype D references 
sequences used on the NCBI website as well as from 
the published and unpublished Iranian sequences from 
the Genbank. 
 
Sequence Analysis 
After allocating a sequence to an HBV genotype by 
analysis of the S gene, the surface gene amino 
acid/nucleotide variations that were found were 
compared with a reference sequence obtained from 
Okamoto (1988, accession number, AB033559)11 and 
HBsAg sequences from Iranian isolates obtained from 
GenBank and NCBI and from our own laboratory 
reports. Comparing to the former, any amino acid 
changes defined as “variant” (host HLA-determined). 
With regards to the latter (Iranian database sequences), 
amino acid differences were defined as “mutation”. 
Sequences have been submitted to GenBank, numbered 
from HM348682-HM348693. 
 
Phylogenetic Analysis 
The evolutionary history was inferred using the 
Neighbor-Joining method. The bootstrap consensus tree 
inferred from 1000 replicates was taken to represent the 
evolutionary history of the taxa analyzed. The 
evolutionary distances were computed using the 
Kimura 2-parameter method and were in the units of 
the number of base substitutions per site. Codon 
positions included were 1st+2nd+3rd+Noncoding. All 
positions containing gaps and missing data were 
eliminated from the dataset (Complete deletion option). 
There were a total of 681 positions in the final dataset. 
Phylogenetic analyses were conducted in MEGA4.12 
 
RESULTS 
 
Twelve HBsAg-positive patients infected with HBV 
were enrolled in this study. All patients were native 
residents of Khoozestan province (south of Iran). The 
group studied consisted of in-active chronic hepatitis B 
carriers, all but one were anti-HBe positive with 
various levels of low to moderate HBV viral load and 
normal to slightly high levels of ALT (>30 in male and 
>19 in female). All were positive for anti-HBc, 
however, negative for anti-HBs (results not shown). 
 
Phylogenetic Analysis 
The results of the phylogenetic tree revealed that 
Iranian HBV isolates from Khoozestan were of 
genotype D and subgenotype D1 supported by 95% and 
97% bootstrap value (1,000 replicates), respectively 
(Figure 1). In the phylogenetic tree, a genotype E 
sequence (accession number AB091266) was chosen 
for out grouping. Of two pairs of clusters (168, 177 and 
171, 174), the former contained a mutation, L109Q, 
and the latter did not contain any nucleotide or amino 
acid mutations. The rest of sequences which showed 
separate individual clusters with different genetic 
distances within the tree were not characterized by 
amino acid substitution specifying that clustering 
patterns. Isolate 167 which showed the highest genetic 
distance was separated from all other strains, which 
contained the largest number of nucleotide and amino 
acid variations, including one stop codon at residue 69 
of surface protein. 
 
Substitutions in Comparison with Reference 
Genotype D (Okamoto, AB033559) 
Overall, comparing with reference sequence 
(Okamoto, 1988), at the nucleotide level, of a total of 
116 changes in 28 positions, 86 (74%) and 30 (26%) 
were silent and missense, respectively (results not 
shown). 
At the amino acid levels, all contained A70P 
compared to Okamoto reference. We believe that this 
substitution was assigned as “variant” (see material and 
methods). According to the above mentioned 
description, 19 out of 49 amino acid changes were 
variants and the other 30 changes were mutations (see 
below). 
 
Genotyping 
Analysis of variation within the S gene of 12 
patients with chronic HBV infection demonstrated that 
the only detected subtype was D (100%), subgenotype 
D1 (100%) and subtype ayw2 (100%) (Figure 1). 
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Figure 1. Neighbour joining phylogenetic trees of surface genes sequences from 12 samples. Note: S gene tree rooted with 
sequence AB049609 (reference genotype C). All Iranian isolates were compared to sequence AB033559 (reference genotype 
D, see the text). The figure shows bootstrap values of ≥70% and scale denotes percent diversity. Coding numbers indicate 
samples that have been analyzed in the figure. The percentage of replicate trees in which the associated taxa clustered 
together in the bootstrap test (1000 replicates) is shown next to the branches. Branches corresponding to partitions 
reproduced in less than 50% bootstrap replicates are collapsed. 
 
 
Table 2. Nucleotide (total and missense) and amino acid substitutions as well as the levels of mutation frequencies between 
isolates deduced from the number and the percentage of individual sequences. 
Sample 
Code 
Total Nucleotide 
Mutations 
Nucleotide Misssense 
Mutation 
Amino Acid Change 
Mutation 
Frequency 
167 G131A, A201G, T207A, A327G, 
A343G, A360C, T427C, T465C 
G131A, T207A, A343G, 
T427C 
G44E, C69Stop, 
T115A, S143P 
1.00 
168 T326A T326A L109Q 1.00 
169 C345T   0.00 
170 [C134A, T135G], C414T, G620C [C134A, T135G], G620C T45K, S207T 3.00 
171    0.00 
172 G71A G71A R24K 1.00 
174    0.00 
176 G131A G131A G44E 1.00 
177 T326A T326A L109Q 1.00 
178 C88A, A201G, T239C, T465C C88A, T239C Q30K, F80S 1.00 
179 T135C, C167A, T310C, T337A, 
C345T, T465C 
C167A, T337A P56Q, S113T 0.50 
180 G40A, T326A, T400G G40A, T326A, T400G V14M, L109Q, Y134D 3.00 
Average - - 1.8 1.04 
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Table 3. Amino acid mutations within B cell, T helper (Th) and CTL epitopes of HBs proteins. Amino acids are described by 
single letter code and numbered from the beginning of HBsAg. The wild type residues aligned according to genotype D 
consensus sequence. 
 Th Epitope CTL Epitope B cell Epitope 
 
Amino acid position 24 30 44 45 56 80 207 109 113 115 134 143 
Wild type R Q G T P F S L S T Y S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sa
m
pl
e 
co
de
 
167   E       A  P 
168        Q     
169             
170    K   T      
171             
172 K            
174             
176   E          
177        Q     
178  K    S       
179     Q    T    
180        Q   D  
 
 
Nucleotide and Amino Acid Substitutions 
In comparison with Iranian sequences obtained 
from the database as well as from our unpublished data, 
in addition to the genotypic characterization described 
above, the sequences of the strains showed a few 
variability over the regions sequenced. In all, 30 “muta-
tions” occurred at 22 nucleotide positions, of them, 18 
(60 %) were missense (amino acid altering) and 12 
(40%) were silent (no amino acid changing) (Table 2). 
At amino acid level, 17 substitutions occurred. 
Furthermore, it was possible to identify the level of S 
protein evolution between isolates by measuring the 
mutation frequency of individual sequences (Table 2). 
The average mutation frequency of all sequences was 
1.5 according to dN/dS) missense to silent mutations 
per site. The average number of amino acid mutations 
for all isolates was 1.8. 
 
Amino Acid Mutations within the Surface Protein 
Immune Epitopes 
15 (88%) out of 17 amino acid mutations occurred 
in different immune epitopes within surface protein, of 
which 7 (46.6%) in B cell epitopes in 5 residues; 7 
(46.6%) in T helper epitopes in 6 positions; 1 (7%)  
in inside CTL epitopes in 1 residue (Table 3). Two 
mutations occurred in “a” determinant: Y134D and 
S143P. 
There were no significant correlations between the 
occurrence and distribution of mutations with age, 
gender, ALT levels and HBeAg status of the patients 
(results not shown). 
 
DISCUSSION 
 
It was possible to sequence the S gene for 12 HBV 
strains from Khoozestan province. Genotype D, 
subgenotype D1 and subtype ayw2 accounted for 100% 
of isolates.  Published and unpublished data from our 
laboratory indicated that in Iran, there has been an 
obvious predominance of these virus genetic 
patterns.13,14 We already hypothesized that this unique 
pattern of homology is related to the relative recent 
distribution and circulation of  HBV in Iran compared 
to other countries in the region.14 
The ratio between silent and missense nucleotide 
mutations in our patients was about 0.66. This indicated 
that the proportion of deduced amino acid changes in 
these chronically infected patients was tremendously 
high, and that these proteins were under a significant 
positive selection pressure which had already been 
applied by humoral host immune system: 15 (88%) out 
of 17 amino acid mutations occurred in different 
immune epitopes within surface protein. It is not 
unexpected, as with prolonged period of chronicity, 
especially in the presence of anti-HBe, the emergence 
of frequent mutations in these patients is inevitable. 
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However, the relative importance of such mutations in 
different immune epitopes within HBV proteins in the 
hierarchy of protective immunity is a matter of debates. 
In terms of HBV proteins, some authors believe that 
CTL epitopes have a major role; a majority of chronic 
HBV carriers contained mutated residues within CTL 
epitopes.15-17 Others, however, showed that these 
mutations occurred in the Th/B cell epitopes.18-21 In our 
group-studied, nearly, half of the of mutations (46.6%) 
were occurred in B cell epitope within major 
hydrophilic region (MHR), encompassing amino acid 
residues 100-160. This was in concordance to our 
previous data. In vitro, we already showed that 
intracellular localization of HBcAg depended on the 
presence of mutations in different hepatitis B core gene 
B cell epitope mutations.22 Of 26 cloned samples, 
HBcAg was predominantly localized in nucleus in 13 
samples in remission phase (as HBcAg is a nuclear 
antigen) and in cytoplasm in other 13 samples with 
active hepatitis. All samples with cytoplasmic 
localization contained B cell epitope mutations. 
Reversion of mutant sequences with cytoplasmic 
expression back to the wild type by mutagenesis led to 
shifting back to nuclear distribution.22 Furthermore, the 
similar numbers of mutations occurred in T helper 
immune epitopes within the surface proteins. The main 
role of T helper subsets in the immunosurveillance 
system is to synthesize cytokines and growth factors 
that stimulate (help) specific lymphocytes, including B 
cells.  
Taken together, substitutions of 93.2% of amino 
acids in B and T helper residues highlights the 
importance of the humoral arm of immune system in 
the pathogenesis of HBV chronicity. The consequence 
of selection pressure posed by anti-S antibodies would 
be the emergence of immune escape mutations in this 
protein which no longer can be recognized by the host 
immune system. Some mutations are able to impair the 
binding of neutralizing antibodies to the viral surface 
(especially at “a” determinant region); viruses carrying 
such mutated T-cell epitopes cannot be recognized by 
specific T-cells of an individual, hence, will not 
enhance anti-HBs production,23 and this can lead to the 
progression of chronicity of hepatitis B virus infection. 
Also, the occurrence of Th and CTL epiotpe mutations 
indicates an ineffective T cell response, as already 
shown that these responses are weak and sometimes 
undetectable during the chronic state of the infection.24 
The results presented in this paper are not defined by 
comparing HBV sequences at different time points for 
the same individuals. Rather, it is defined by its 
occurrence in highly conserved positions. 
In conclusion, it appears from this work that there 
are variations in the structural protein of HBV in 
chronic patients. For a better interpretation, the 
allocation of such molecular variations to the clinical, 
serological and biochemical pictures needs to be 
explored. In this scenario, even an individual variation 
must be taken into account. 
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